Immunotherapy, using a patient’s own immune system to treat disease, has shown promise in some patients with cancer but has not worked in most. New research from St. Jude Children’s Research Hospital and colleagues has found that disrupting Asxl1, a gene in T cells, improved sensitivity to a type of immunotherapy called immune checkpoint blockade and improved long-term tumor control in model systems. The findings appear in Science.
Medical Xpress – latest medical and health news stories
